Trial Profile
A Pilot Phase I Study of Atezolizumab (MPDL3280A) in Combination With Immunogenic Chemotherapy (Gemcitabine-Oxaliplatin) and Rituximab for Transformed Diffuse Large B-Cell Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Gemcitabine; Oxaliplatin; Rituximab
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions
- 14 Feb 2024 Planned End Date changed from 31 Jan 2024 to 31 Mar 2025.
- 14 Feb 2024 Planned primary completion date changed from 31 Jan 2024 to 31 Mar 2025.
- 21 Jul 2023 Planned End Date changed from 30 Jun 2023 to 31 Jan 2024.